GLP-1 RA vs DPP-4i Reduces Major CV, Kidney Risks in Lupus With Diabetes
A trial emulation assessed the impact of GLP-1RA use on cardiovascular, kidney, and death outcomes in patients with systemic lupus erythematosus.
Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) is linked with lower risks of major adverse cardiovascular events (MACE), progression of kidney disease, venous thromboembolism (VTE), and all-cause mortality compared with dipeptidyl peptidase 4 inhibitor (DPP4i) therapy in patients with systemic lupus erythematosus (SLE) and type 2 diabetes (T2D).
The study included 910 initiators of GLP-1RAs and 1004 initiators of DPP4is with SLE, with similar reductions in risks for MACE and progression of kidney disease observed among patients with lupus nephritis (LN).
Results from an emulated target trial published in Arthritis and Rheumatology.
Author's summary: GLP-1 RA reduces CV and kidney risks in lupus patients with diabetes.